Universal varicella vaccination in Denmark
Modeling public health impact, age-shift, and cost-effectiveness
Bibliographic Data
| ID | 19591185 |
|---|---|
| Authors | Colleen Burgess (0000-0003-0393-0767, Merck & Co., Inc., Rahway, NJ, USA (United States), corresponding author), Salome Samant (0000-0001-6176-0677, Merck & Co., Inc., Rahway, NJ, USA (United States), corresponding author), Thomas Lefèvre (0000-0003-0260-2147, corresponding author), Carsten Schade Larsen (0000-0002-3963-3804, Aarhus University Hospital, corresponding author), Manjiri Pawaskar (0000-0001-8009-805X, Merck & Co., Inc., Rahway, NJ, USA (United States), corresponding author) |
| Editors | Edina Amponsah-Dacosta (0000-0002-3913-0457) |
| Year | 2023 |
| Volume | 3 |
| Issue | 4 |
| Pages | e0001743 |
| Publication date | 2023-04-05 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | PLOS Global Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2767-3375 • E-ISSN: 2767-3375 |
| Publisher | Public Library of Science (PLoS) (PUBLISHER) |
| DOI | 10.1371/journal.pgph.0001743 |
| PMID | 37018165 |
| OpenAlex | W4362602127 |
| Language | IT |
| References cited | 20 |
We modeled the long-term clinical and economic impact of two-dose universal varicella vaccination (UVV) strategies in Denmark using a dynamic transmission model. The cost-effectiveness of UVV was evaluated along with the impact on varicella (including age-shift) and herpes zoster burden. Six two-dose UVV strategies were compared to no vaccination, at either short (12/15 months) or medium (15/48 months) intervals. Monovalent vaccines (V-MSD or V-GSK) for the 1 st dose, and either monovalent or quadrivalent vaccines (MMRV-MSD or MMRV-GSK) for the 2 nd dose were considered. Compared to no vaccination, all two-dose UVV strategies reduced varicella cases by 94%-96%, hospitalizations by 93%-94%, and deaths by 91%-92% over 50 years; herpes zoster cases were also reduced by 9%. There was a decline in the total number of annual varicella cases in all age groups including adolescents and adults. All UVV strategies were cost-effective compared to no vaccination, with ICER values ranging from €18,228-€20,263/QALY (payer perspective) and €3,746-€5,937/QALY (societal perspective). The frontier analysis showed that a two-dose strategy with V-MSD (15 months) and MMRV-MSD (48 months) dominated all other strategies and was the most cost-effective. In conclusion, all modeled two-dose UVV strategies were projected to substantially reduce the clinical and economic burden of varicella disease in Denmark compared to the current no vaccination strategy, with declines in both varicella and zoster incidence for all age groups over a 50-year time horizon
Immunization · Vaccination · Varicella vaccine · Varicella zoster virus · Virus · Bartonella species infections research · Hepatitis Viruses Studies and Epidemiology · Herpesvirus Infections and Treatments · Medicine · Immunology · Pediatrics · Virology
| Highly cited | No |
|---|